182 related articles for article (PubMed ID: 31216324)
21. Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes.
Fujishima Y; Maeda N; Inoue K; Kashine S; Nishizawa H; Hirata A; Kozawa J; Yasuda T; Okita K; Imagawa A; Funahashi T; Shimomura I
Cardiovasc Diabetol; 2012 Sep; 11():107. PubMed ID: 22973968
[TBL] [Abstract][Full Text] [Related]
22. Associations between changes in glucagon-like peptide-1 and bodyweight reduction in patients receiving acarbose or metformin treatment.
Wang N; Zhang JP; Xing XY; Yang ZJ; Zhang B; Wang X; Yang WY
J Diabetes; 2017 Aug; 9(8):728-737. PubMed ID: 27717194
[TBL] [Abstract][Full Text] [Related]
23. Comparison of A1c Reduction, Weight Loss, and Changes in Insulin Requirements With Addition of GLP-1 Agonists vs SGLT-2 Inhibitors in Patients Using Multiple Daily Insulin Injections.
Wehrman G; Halton M; Riveland B; Potter E; Gaddy M
J Pharm Pract; 2024 Apr; 37(2):311-317. PubMed ID: 36227709
[No Abstract] [Full Text] [Related]
24. Combination Therapy With Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Older Patients With Type 2 Diabetes: A Real-World Evidence Study.
Carretero Gómez J; Arévalo Lorido JC; Gómez Huelgas R; García de Lucas D; Mateos Polo L; Varela Aguilar JM; Seguí Ripoll JM; Ena J;
Can J Diabetes; 2019 Apr; 43(3):186-192. PubMed ID: 30415909
[TBL] [Abstract][Full Text] [Related]
25. Glycaemic control in the diabetes and Lifestyle Cohort Twente: A cross-sectional assessment of lifestyle and pharmacological management on Hba1c target achievement.
Jalving AC; Gant CM; Binnenmars SH; Soedamah-Muthu SS; Bakker SJL; Navis G; Laverman GD
Diabetes Obes Metab; 2018 Oct; 20(10):2494-2499. PubMed ID: 29862616
[TBL] [Abstract][Full Text] [Related]
26. Correlation between baseline characteristics and clinical outcomes in a large population of diabetes patients treated with liraglutide in a real-world setting in Italy.
Lapolla A; Frison V; Bettio M; Dal Pos M; Rocchini P; Panebianco G; Tadiotto F; Da Tos V; D'Ambrosio M; Marangoni A; Ferrari M; Pianta A; Balzano S; Confortin L; Lamonica M; Marin N; Strazzabosco M; Brun E; Mesturino CA; Simoncini M; Zen F; Bax G; Bonsembiante B; Cardone C; Dal Frà MG; Gallo A; Masin M; Piarulli F; Sartore G; Simioni N
Clin Ther; 2015 Mar; 37(3):574-84. PubMed ID: 25626486
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
Frias JP; Nauck MA; Van J; Kutner ME; Cui X; Benson C; Urva S; Gimeno RE; Milicevic Z; Robins D; Haupt A
Lancet; 2018 Nov; 392(10160):2180-2193. PubMed ID: 30293770
[TBL] [Abstract][Full Text] [Related]
28. Lifestyle change reduces cardiometabolic risk factors and glucagon-like peptide-1 levels in obese first-degree relatives of people with diabetes.
Bowes A; Begley J; Kerr D
J Hum Nutr Diet; 2017 Aug; 30(4):490-498. PubMed ID: 28168767
[TBL] [Abstract][Full Text] [Related]
29. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
[TBL] [Abstract][Full Text] [Related]
30. GLP1-RA Add-on Therapy in Patients with Type 2 Diabetes Currently on a Bolus Containing Insulin Regimen.
Davies ML; Pham DQ; Drab SR
Pharmacotherapy; 2016 Aug; 36(8):893-905. PubMed ID: 27340935
[TBL] [Abstract][Full Text] [Related]
31. Effect of Hemoglobin A1c Reduction or Weight Reduction on Blood Pressure in Glucagon-Like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter-2 Inhibitor Treatment in Type 2 Diabetes Mellitus: A Meta-Analysis.
Hu M; Cai X; Yang W; Zhang S; Nie L; Ji L
J Am Heart Assoc; 2020 Apr; 9(7):e015323. PubMed ID: 32223390
[TBL] [Abstract][Full Text] [Related]
32. Glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors as add-on therapy for patients with type 2 diabetes? A systematic review and meta-analysis of surrogate metabolic endpoints.
Patoulias D; Katsimardou A; Kalogirou MS; Zografou I; Toumpourleka M; Imprialos K; Stavropoulos K; Stergiou I; Papadopoulos C; Doumas M
Diabetes Metab; 2020 Sep; 46(4):272-279. PubMed ID: 32437914
[TBL] [Abstract][Full Text] [Related]
33. Real-world weight-loss effectiveness of glucagon-like peptide-1 agonists among patients with type 2 diabetes: A retrospective cohort study.
White GE; Shu I; Rometo D; Arnold J; Korytkowski M; Luo J
Obesity (Silver Spring); 2023 Feb; 31(2):537-544. PubMed ID: 36621904
[TBL] [Abstract][Full Text] [Related]
34. Adherence to NICE guidance on glucagon-like peptide-1 receptor agonists among patients with type 2 diabetes mellitus: an evaluation using the Clinical Practice Research Datalink.
Jameson K; D'Oca K; Leigh P; Murray-Thomas T
Curr Med Res Opin; 2016; 32(1):49-60. PubMed ID: 26428701
[TBL] [Abstract][Full Text] [Related]
35. The effects of glucagon-like peptide-1 receptor agonists on glycemic control and anthropometric profiles among diabetic patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials.
Nowrouzi-Sohrabi P; Rezaei S; Jalali M; Ashourpour M; Ahmadipour A; Keshavarz P; Akbari H
Eur J Pharmacol; 2021 Feb; 893():173823. PubMed ID: 33352183
[TBL] [Abstract][Full Text] [Related]
36. Glycemic Control and Weight Outcomes for Exenatide Once Weekly Versus Liraglutide in Patients with Type 2 Diabetes: A 1-Year Retrospective Cohort Analysis.
McAdam-Marx C; Nguyen H; Schauerhamer MB; Singhal M; Unni S; Ye X; Cobden D
Clin Ther; 2016 Dec; 38(12):2642-2651. PubMed ID: 27889301
[TBL] [Abstract][Full Text] [Related]
37. Weight gain in insulin-treated patients by body mass index category at treatment initiation: new evidence from real-world data in patients with type 2 diabetes.
Paul SK; Shaw JE; Montvida O; Klein K
Diabetes Obes Metab; 2016 Dec; 18(12):1244-1252. PubMed ID: 27502528
[TBL] [Abstract][Full Text] [Related]
38. Values, preferences and burden of treatment for the initiation of GLP-1 receptor agonists and SGLT-2 inhibitors in adult patients with type 2 diabetes: a systematic review.
González-González JG; Díaz González-Colmenero A; Millán-Alanís JM; Lytvyn L; Solis RC; Mustafa RA; Palmer SC; Li S; Hao Q; Alvarez-Villalobos NA; Vandvik PO; Rodríguez-Gutiérrez R
BMJ Open; 2021 Jul; 11(7):e049130. PubMed ID: 34244276
[TBL] [Abstract][Full Text] [Related]
39. Glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes:real-world evidence from a Mediterranean area.
Mata-Cases M; Franch-Nadal J; Ortega E; Real J; Gratacòs M; Vlacho B; Mauricio D
Curr Med Res Opin; 2019 Oct; 35(10):1735-1744. PubMed ID: 31081693
[No Abstract] [Full Text] [Related]
40. Weight loss differences seen between glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors for treatment of type 2 diabetes.
Frieling K; Monte SV; Jacobs D; Albanese NP
J Am Pharm Assoc (2003); 2021; 61(6):772-777. PubMed ID: 34266747
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
